

## Electronic Supplementary Information

# Improved Monitoring of Aqueous Samples by the Preconcentration of Active Pharmaceutical Ingredients using Ionic-Liquid-based Systems

*Hugo F. D. Almeida<sup>a,b</sup>, Mara G. Freire<sup>b\*</sup> and Isabel M. Marrucho<sup>a,c\*</sup>*

<sup>a</sup>Instituto de Tecnologia Química e Biológica António Xavier, Universidade Nova de  
Lisboa, 2780-157 Oeiras, Portugal.

<sup>b</sup>CICECO – Aveiro Institute of Materials, Chemistry Department, University of Aveiro,  
3810-193 Aveiro, Portugal.

<sup>c</sup>Centro de Química Estrutural, Instituto Superior Técnico, Universidade de Lisboa,  
Avenida Rovisco Pais, 1049-001 Lisboa, Portugal.

\*Corresponding authors: [imarrucho@itqb.unl.pt](mailto:imarrucho@itqb.unl.pt); [maragfreire@ua.pt](mailto:maragfreire@ua.pt)

### Determination of Tie-Lines (TLs) and Tie-Line Lengths (TLLs)

The specific composition of each phase in equilibrium was determined based on the initial mixture composition and on the weight of each phase, using the following equations (eqs. (1) – (4)) with four unknown values ( $[IL]_{IL}$ ,  $[IL]_{salt}$ ,  $[salt]_{IL}$ ,  $[salt]_{salt}$ ):<sup>1</sup>

$$[IL]_{IL} = A \exp[(B \times [salt]_{IL}^{0.5}) - (C \times [salt]_{IL}^3)] \quad (1)$$

$$[IL]_{salt} = A \exp[(B \times [salt]_{salt}^{0.5}) - (C \times [salt]_{salt}^3)] \quad (2)$$

$$[IL]_{IL} = \frac{[IL]_M}{\alpha} - \frac{1-\alpha}{\alpha} \times [IL]_{salt} \quad (3)$$

$$[salt]_{IL} = \frac{[salt]_M}{\alpha} - \frac{1-\alpha}{\alpha} \times [salt]_{salt} \quad (4)$$

where IL, salt and M are the ionic-liquid-rich phase, the salt-rich phase and the mixture, respectively.  $[IL]$  and  $[salt]$  correspond to the weight fraction percentage of ionic liquid and salt, respectively, and  $\alpha$  is the ratio between the weight of the ionic-liquid-rich phase and the total mass of the mixture.

For the calculation of the tie-line length (TLL), the following equation was used:

$$TLL = \sqrt{([salt]_{IL} - [salt]_{salt})^2 + ([IL]_{IL} - [IL]_{salt})^2} \quad (5)$$

where IL and salt represents the ionic-liquid-rich phase and salt-rich phase, respectively.  $[IL]$  and  $[salt]$  correspond to the weight fraction percentage of ionic liquid and salt, as described before.

## Extraction and concentration of APIs using IL-based ABS

**Table S.I. 1.** Weight fraction percentage (wt%) of each compound in the coexisting phases of the ABS investigated.

Fluoroquinolones						
Weight fraction percentage / wt%						
Ionic Liquid	[IL] <sub>salt</sub>	[salt] <sub>salt</sub>	[IL] <sub>M</sub>	[salt] <sub>M</sub>	[IL] <sub>IL</sub>	[salt] <sub>IL</sub>
[P <sub>4444</sub> ]Cl	2.7	40.3	40.2	18.8	66.5	3.8
[N <sub>4444</sub> ]Cl	1.9	46.4	39.8	18.8	62.8	2.1
[C <sub>4</sub> C <sub>1</sub> pip][Cl	3.1	58.9	40.1	18.9	51.9	6.1
[C <sub>4</sub> C <sub>1</sub> pyr]Cl	5.6	54.1	40.0	18.9	53.1	5.5
[C <sub>4</sub> C <sub>1</sub> im]Cl	9.1	48.9	39.9	18.8	49.9	8.9
[C <sub>8</sub> C <sub>1</sub> im]Cl	12.7	44.4	39.9	18.7	46.9	12.2
[C <sub>4</sub> C <sub>1</sub> im]Br	4.6	43.1	39.9	18.9	63.7	2.7
[C <sub>4</sub> C <sub>1</sub> im][SCN]	0.0	34.7	40.1	19.0	87.4	0.5
[C <sub>4</sub> C <sub>1</sub> im][N(CN) <sub>2</sub> ]	0.1	40.6	39.8	18.9	71.9	1.4
[C <sub>4</sub> C <sub>1</sub> im][CF <sub>3</sub> SO <sub>3</sub> ]	1.1	34.2	40.1	19.0	85.7	1.2
Non-steroidal anti-inflammatory drugs						
Weight fraction percentage / wt%						
Ionic Liquid	[IL] <sub>salt</sub>	[salt] <sub>salt</sub>	[IL] <sub>M</sub>	[salt] <sub>M</sub>	[IL] <sub>IL</sub>	[salt] <sub>IL</sub>
[P <sub>4444</sub> ]Cl	2.8	40.1	40.0	18.9	66.7	3.7
[N <sub>4444</sub> ]Cl	2.1	45.9	40.0	18.9	64.0	1.9
[C <sub>4</sub> C <sub>1</sub> pip][Cl	3.1	58.8	39.8	18.9	51.6	6.2
[C <sub>4</sub> C <sub>1</sub> pyr]Cl	2.9	61.4	40.1	18.9	51.0	6.4
[C <sub>4</sub> C <sub>1</sub> im]Cl	9.6	48.2	40.0	18.9	51.1	8.2
[C <sub>8</sub> C <sub>1</sub> im]Cl	11.9	45.6	40.0	18.8	47.2	12.0
[C <sub>4</sub> C <sub>1</sub> im]Br	4.4	43.6	40.0	18.9	63.4	2.7
[C <sub>4</sub> C <sub>1</sub> im][SCN]	0.1	34.6	40.1	19.0	87.6	0.4
[C <sub>4</sub> C <sub>1</sub> im][N(CN) <sub>2</sub> ]	0.0	43.3	39.8	18.8	67.3	1.5
[C <sub>4</sub> C <sub>1</sub> im][CF <sub>3</sub> SO <sub>3</sub> ]	1.0	34.3	40.0	19.0	85.4	1.0

**Table S.I. 2.** Tie-line length (TLL), pH of the IL-rich phase (pH<sub>IL</sub>), and extraction efficiencies of the studied fluoroquinolones (%EE<sub>FQs</sub>), and corresponding standard deviations ( $\sigma$ ).

<i>Ciprofloxacin</i>			
<b>Ionic Liquid</b>	<b>TLL <math>\pm \sigma</math></b>	<b>pH<sub>IL</sub> <math>\pm \sigma</math></b>	<b>%EE<sub>FQs</sub> <math>\pm \sigma</math></b>
[P4444]Cl	73.3 $\pm$ 0.3	8.52 $\pm$ 0.04	99.80 $\pm$ 0.39
[N4444]Cl	75.5 $\pm$ 0.3	9.91 $\pm$ 0.06	99.37 $\pm$ 0.73
[C4C1pip][Cl]	72.7 $\pm$ 1.1	9.51 $\pm$ 0.03	99.29 $\pm$ 0.59
[C4C1pyr][Cl]	68.9 $\pm$ 1.3	9.31 $\pm$ 0.01	98.82 $\pm$ 0.23
[C4C1im]Cl	58.1 $\pm$ 1.3	9.08 $\pm$ 0.02	99.28 $\pm$ 0.43
[C8C1im]Cl	47.4 $\pm$ 0.6	7.37 $\pm$ 0.01	99.29 $\pm$ 0.37
[C4C1im]Br	71.5 $\pm$ 0.2	8.23 $\pm$ 0.02	93.06 $\pm$ 1.96
[C4C1im][SCN]	93.8 $\pm$ 0.5	7.59 $\pm$ 0.03	62.72 $\pm$ 0.22
[C4C1im][N(CN) <sub>2</sub> ]	81.8 $\pm$ 0.0	9.14 $\pm$ 0.01	98.13 $\pm$ 0.32
[C4C1im][CF <sub>3</sub> SO <sub>3</sub> ]	90.8 $\pm$ 1.1	8.04 $\pm$ 0.04	61.33 $\pm$ 2.58
<i>Norfloxacin</i>			
<b>Ionic Liquid</b>	<b>TLL <math>\pm \sigma</math></b>	<b>pH<sub>IL</sub> <math>\pm \sigma</math></b>	<b>%EE<sub>FQs</sub> <math>\pm \sigma</math></b>
[P4444]Cl	73.3 $\pm$ 0.3	8.61 $\pm$ 0.04	98.35 $\pm$ 3.29
[N4444]Cl	76.2 $\pm$ 0.5	9.95 $\pm$ 0.09	99.36 $\pm$ 0.72
[C4C1pip][Cl]	70.7 $\pm$ 1.1	9.52 $\pm$ 0.01	93.62 $\pm$ 0.52
[C4C1pyr][Cl]	67.5 $\pm$ 0.1	9.28 $\pm$ 0.02	98.84 $\pm$ 0.16
[C4C1im]Cl	58.7 $\pm$ 0.4	9.08 $\pm$ 0.02	99.16 $\pm$ 0.25
[C8C1im]Cl	45.9 $\pm$ 1.0	7.37 $\pm$ 0.01	98.96 $\pm$ 0.40
[C4C1im]Br	71.9 $\pm$ 0.0	8.14 $\pm$ 0.02	95.32 $\pm$ 2.24
[C4C1im][SCN]	93.5 $\pm$ 0.6	7.50 $\pm$ 0.05	62.83 $\pm$ 0.87
[C4C1im][N(CN) <sub>2</sub> ]	80.8 $\pm$ 0.0	9.12 $\pm$ 0.04	96.62 $\pm$ 0.20
[C4C1im][CF <sub>3</sub> SO <sub>3</sub> ]	90.4 $\pm$ 0.9	7.50 $\pm$ 0.01	58.83 $\pm$ 0.83
<i>Enrofloxacin</i>			
<b>Ionic Liquid</b>	<b>TLL <math>\pm \sigma</math></b>	<b>pH<sub>IL</sub> <math>\pm \sigma</math></b>	<b>%EE<sub>FQs</sub> <math>\pm \sigma</math></b>
[P4444]Cl	72.7 $\pm$ 0.4	8.22 $\pm$ 0.03	97.28 $\pm$ 0.78
[N4444]Cl	75.9 $\pm$ 0.1	9.78 $\pm$ 0.00	99.44 $\pm$ 1.13
[C4C1pip][Cl]	71.0 $\pm$ 0.6	9.72 $\pm$ 0.04	99.35 $\pm$ 0.31
[C4C1pyr][Cl]	58.2 $\pm$ 0.0	9.15 $\pm$ 0.02	99.55 $\pm$ 0.35
[C4C1im]Cl	60.1 $\pm$ 0.3	9.52 $\pm$ 0.04	99.66 $\pm$ 0.68
[C8C1im]Cl	46.0 $\pm$ 0.6	7.39 $\pm$ 0.01	99.35 $\pm$ 0.31
[C4C1im]Br	72.2 $\pm$ 0.1	8.57 $\pm$ 0.01	97.57 $\pm$ 1.87
[C4C1im][SCN]	93.9 $\pm$ 1.0	7.59 $\pm$ 0.03	95.16 $\pm$ 0.63
[C4C1im][N(CN) <sub>2</sub> ]	82.6 $\pm$ 0.0	9.15 $\pm$ 0.03	99.60 $\pm$ 0.11
[C4C1im][CF <sub>3</sub> SO <sub>3</sub> ]	90.1 $\pm$ 0.8	7.98 $\pm$ 0.13	90.89 $\pm$ 2.42

**Table S.I. 3.** Tie-line length (TLL), pH of the IL-rich phase ( $\text{pH}_{\text{IL}}$ ), and extraction efficiencies of the studied non-steroidal anti-inflammatory drugs ( $\%EE_{\text{NSAIDs}}$ ), and corresponding standard deviations ( $\sigma$ ).

<i>Diclofenac</i>			
<b>Ionic Liquid</b>	<b>TLL <math>\pm \sigma</math></b>	<b>pH<sub>IL</sub> <math>\pm \sigma</math></b>	<b>%EE<sub>NSAIDs</sub> <math>\pm \sigma</math></b>
[P4444]Cl	73.5 $\pm$ 0.3	9.55 $\pm$ 0.06	99.55 $\pm$ 0.81
[N4444]Cl	76.0 $\pm$ 0.1	9.90 $\pm$ 0.04	99.71 $\pm$ 0.70
[C4C1pip][Cl]	72.4 $\pm$ 1.3	9.51 $\pm$ 0.03	99.65 $\pm$ 0.16
[C4C1pyr]Cl	70.6 $\pm$ 3.6	9.56 $\pm$ 0.01	99.21 $\pm$ 0.69
[C4C1im]Cl	57.7 $\pm$ 1.7	8.72 $\pm$ 0.02	97.65 $\pm$ 2.82
[C8C1im]Cl	48.8 $\pm$ 0.8	7.38 $\pm$ 0.01	99.22 $\pm$ 0.38
[C4C1im]Br	71.8 $\pm$ 0.6	8.35 $\pm$ 0.02	96.16 $\pm$ 2.44
[C4C1im][SCN]	93.7 $\pm$ 0.4	7.68 $\pm$ 0.03	97.42 $\pm$ 2.46
[C4C1im][N(CN) <sub>2</sub> ]	80.0 $\pm$ 1.3	9.33 $\pm$ 0.01	95.61 $\pm$ 0.85
[C4C1im][CF <sub>3</sub> SO <sub>3</sub> ]	90.1 $\pm$ 0.8	7.90 $\pm$ 0.04	96.41 $\pm$ 2.66
<i>Naproxen</i>			
<b>Ionic Liquid</b>	<b>TLL <math>\pm \sigma</math></b>	<b>pH<sub>IL</sub> <math>\pm \sigma</math></b>	<b>%EE<sub>NSAIDs</sub> <math>\pm \sigma</math></b>
[P4444]Cl	76.1 $\pm$ 0.1	9.19 $\pm$ 0.04	95.44 $\pm$ 2.96
[N4444]Cl	78.9 $\pm$ 0.1	9.20 $\pm$ 0.10	99.75 $\pm$ 0.01
[C4C1pip][Cl]	71.2 $\pm$ 1.2	9.52 $\pm$ 0.01	95.65 $\pm$ 2.57
[C4C1pyr]Cl	70.3 $\pm$ 1.7	9.58 $\pm$ 0.02	98.21 $\pm$ 1.50
[C4C1im]Cl	67.4 $\pm$ 0.5	8.74 $\pm$ 0.02	97.98 $\pm$ 1.86
[C8C1im]Cl	47.4 $\pm$ 0.7	7.36 $\pm$ 0.01	99.34 $\pm$ 0.24
[C4C1im]Br	75.7 $\pm$ 0.1	8.45 $\pm$ 0.03	92.32 $\pm$ 5.33
[C4C1im][SCN]	93.6 $\pm$ 0.7	7.62 $\pm$ 0.05	83.14 $\pm$ 1.31
[C4C1im][N(CN) <sub>2</sub> ]	82.4 $\pm$ 0.1	9.29 $\pm$ 0.04	93.10 $\pm$ 6.50
[C4C1im][CF <sub>3</sub> SO <sub>3</sub> ]	90.3 $\pm$ 0.8	7.84 $\pm$ 0.01	96.06 $\pm$ 1.72
<i>Ketoprofen</i>			
<b>Ionic Liquid</b>	<b>TLL <math>\pm \sigma</math></b>	<b>pH<sub>IL</sub> <math>\pm \sigma</math></b>	<b>%EE<sub>NSAIDs</sub> <math>\pm \sigma</math></b>
[P4444]Cl	72.9 $\pm$ 0.5	9.76 $\pm$ 0.03	92.63 $\pm$ 4.53
[N4444]Cl	77.5 $\pm$ 2.0	9.59 $\pm$ 0.00	99.52 $\pm$ 0.25
[C4C1pip][Cl]	71.0 $\pm$ 0.6	9.72 $\pm$ 0.04	98.96 $\pm$ 0.94
[C4C1pyr]Cl	71.4 $\pm$ 0.9	9.58 $\pm$ 0.02	98.09 $\pm$ 1.82
[C4C1im]Cl	60.5 $\pm$ 1.0	8.79 $\pm$ 0.04	97.33 $\pm$ 4.31
[C8C1im]Cl	45.9 $\pm$ 0.6	7.39 $\pm$ 0.01	93.65 $\pm$ 1.91
[C4C1im]Br	71.6 $\pm$ 0.1	8.37 $\pm$ 0.01	94.46 $\pm$ 5.12
[C4C1im][SCN]	93.8 $\pm$ 1.1	7.70 $\pm$ 0.33	95.32 $\pm$ 3.84
[C4C1im][N(CN) <sub>2</sub> ]	80.4 $\pm$ 0.7	9.34 $\pm$ 0.03	96.53 $\pm$ 1.54
[C4C1im][CF <sub>3</sub> SO <sub>3</sub> ]	90.0 $\pm$ 0.7	7.86 $\pm$ 0.13	85.33 $\pm$ 8.14


**Table S.I. 4.** Initial mixture composition (wt%), percentage extraction efficiencies of ciprofloxacin and diclofenac (%EE<sub>FQs</sub> and % EE<sub>NSAIDs</sub>, respectively) and tie-line length (TLL), with corresponding standard deviations ( $\sigma$ ).

<i>Ciprofloxacin</i>								
IL	Weight fraction percentage / wt%						TLL $\pm \sigma$	% EE <sub>FQs</sub> $\pm \sigma$
	[IL] <sub>salt</sub>	[salt] <sub>salt</sub>	[IL] <sub>M</sub>	[salt] <sub>M</sub>	[IL] <sub>IL</sub>	[salt] <sub>IL</sub>		
	2.8	43.5	39.8	15.1	55.2	3.4	65.82 $\pm$ 0.17	99.75 $\pm$ 0.29
[N <sub>4444</sub> ]Cl	1.9	46.4	39.9	18.8	63.3	2.0	77.51 $\pm$ 0.28	99.37 $\pm$ 0.73
	0.5	53.7	39.9	24.1	71.5	1.0	87.64 $\pm$ 0.35	99.77 $\pm$ 0.27
<i>Diclofenac</i>								
IL	Weight fraction percentage / wt%						TLL $\pm \sigma$	% EE <sub>NSAIDs</sub> $\pm \sigma$
	[IL] <sub>salt</sub>	[salt] <sub>salt</sub>	[IL] <sub>M</sub>	[salt] <sub>M</sub>	[IL] <sub>IL</sub>	[salt] <sub>IL</sub>		
	3.3	41.5	40.2	14.8	56.4	3.1	65.51 $\pm$ 0.66	99.26 $\pm$ 0.51
[N <sub>4444</sub> ]Cl	1.8	46.0	40.1	18.9	64.2	1.9	76.40 $\pm$ 0.17	99.71 $\pm$ 0.70
	0.7	51.8	40.3	24.3	73.9	0.8	89.18 $\pm$ 0.77	99.32 $\pm$ 0.82

**Table S.I. 5.** Percentage extraction efficiencies of ciprofloxacin and diclofenac (%EE<sub>FQs</sub> and % EE<sub>NSAIDs</sub>, respectively) with corresponding standard deviations ( $\sigma$ ), initial mixture composition (wt %) and concentration factor (CF).

<i>Ciprofloxacin</i>				
<b>IL</b>	<b>Weight fraction percentage / wt%</b>		<b>%EE<sub>FQs</sub> ± <math>\sigma</math></b>	<b>CF</b>
	<b>[IL]<sub>M</sub></b>	<b>[salt]<sub>M</sub></b>		
[N <sub>4444</sub> ]Cl	39.92	24.14	99.8 ± 0.3	0.6
	24.35	35.07	99.7 ± 0.4	1.1
	13.98	42.52	99.7 ± 0.5	2.0
	8.07	46.54	99.5 ± 0.8	3.3
	2.99	49.85	99.7 ± 0.4	9.0
	0.53	51.74	99.9 ± 0.2	1084.5
<i>Diclofenac</i>				
<b>IL</b>	<b>Weight fraction percentage / wt%</b>		<b>%EE<sub>NSAIDs</sub> ± <math>\sigma</math></b>	<b>CF</b>
	<b>[IL]<sub>M</sub></b>	<b>[salt]<sub>M</sub></b>		
[N <sub>4444</sub> ]Cl	40.11	24.35	99.3 ± 0.8	0.7
	24.38	35.12	99.6 ± 0.7	1.1
	14.01	42.50	99.4 ± 0.8	2.1
	8.02	46.53	99.0 ± 0.8	3.3
	3.02	50.03	99.1 ± 1.2	8.0
	0.53	51.74	99.9 ± 0.2	1164.4

pKa



Strongest acidic pKa: 5.76  
Strongest basic pKa: 8.68





Figure S.I. 1. Speciation profile of ciprofloxacin as a function of the pH.<sup>3</sup>

pKa



Strongest acidic pKa: 5.77  
Strongest basic pKa: 8.68





Figure S.I. 2. Speciation profile of norfloxacin as a function of the pH.<sup>3</sup>



pKa




Figure S.I. 3. Speciation profile of enrofloxacin as a function of the pH.<sup>3</sup>

pKa






Figure S.I. 4. Speciation profile of diclofenac as a function of the pH.<sup>3</sup>

pKa



Strongest acidic pKa: 4.19






Figure S.I. 5. Speciation profile of naproxen as a function of the pH.<sup>3</sup>

pKa



Strongest acidic pKa: 3.88








Figure S.I. 6. Speciation profile of ketoprofen as a function of the pH.<sup>3</sup>



**Figure S.I. 7.** HPLC-UV chromatograms of (A) ciprofloxacin and (B) diclofenac at different concentrations at 278 nm and 275 nm, respectively. The concentrations used were in the range of 0.0002 to 0.0500 g.L<sup>-1</sup>.



**Figure S.I. 1.** HPLC-UV chromatograms after the ABS concentration step with model systems (distilled water) containing (A) ciprofloxacin and (B) diclofenac at 278 nm and 275 nm, respectively. Circles are representative of ciprofloxacin and diclofenac.



**Figure S.I. 9.** HPLC-UV chromatograms after the ABS concentration step with model systems/distilled water containing a mixture of (A) ciprofloxacin and (B) diclofenac at 278 nm and 275 nm, respectively. Circles are representative of ciprofloxacin and diclofenac.

## References

- 1 J. C. Merchuk, B. A. Andrews and J. A. Asenjo, *Journal of Chromatography B: Biomedical Sciences and Applications*, 1998, **711**, 285-293.
- 2 A. M. Ferreira, J. A. P. Coutinho, A. M. Fernandes and M. G. Freire, *Separation and Purification Technology*, 2014, **128**, 58-66.
- 3 ChemSpider - The free chemical database at [www.chemspider.com](http://www.chemspider.com) (Accessed on October 2015)).